Skip to content

Grape Juice and Dermatitis in Breast Cancer

The Effect of Grape Juice Consumption on Radiotherapy-induced Dermatitis in Breast Cancer - A Pilot Study

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04890184
Enrollment
50
Registered
2021-05-18
Start date
2021-05-08
Completion date
2021-07-15
Last updated
2021-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Brief summary

This study aimed to investigate the effect of grape juice on acute radiation dermatitis in breast cancer (BC) patients undergoing radiotherapy (RT). 50 eligible BC patients will randomly assign to consume 100 gr of grape juice per day during and 1 week after RT or with no intervention (control group). The radiation dermatitis will be assessed weekly according to the Radiation Therapy Oncology Group/ European Organization for Research and Treatment of Cancer (RTOG/EORTC) scales.

Detailed description

Dietary intake of patients will be examined by expert dietitians at baseline and end of RT using the average of three-day 24-hour recalls. Weight (kg), body fat percentage, skeletal muscle percentage and visceral fat level will be measured using the OMRON Body Composition Monitor and Scale.

Interventions

DIETARY_SUPPLEMENTgrape juice

grape juice

OTHERcontrol

no intervention

Sponsors

National Nutrition and Food Technology Institute
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* women with Brest Cancer undergoing adjutant Radiation therapy

Exclusion criteria

* previous history of RT, MRM, * concomitant presence of two or more malignant tumors * metastasis to other areas * allergy or intolerance to tahini * skin diseases and wounds * severe liver and renal disease * autoimmune diseases * pregnant and lactating women * those who treated with hypo fraction RT

Design outcomes

Primary

MeasureTime frameDescription
severity of dermatitis4 weeksChange from Baseline severity at 4 weeks. The radiation dermatitis will be assessed according to the Radiation Therapy Oncology Group/ European Organization for Research and Treatment of Cancer (RTOG/EORTC) scales

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026